BRIDGING THE GAP IN ACNE MANAGEMENT: A NARRATIVE REVIEW OF CURRENT THERAPIES AND THE EMERGENCE OF CLASCOTERONE
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5705Keywords:
Acne Vulgaris, Clascoterone, Emerging TherapiesAbstract
Acne vulgaris is one of the most common dermatological conditions worldwide, estimated to affect up to 85–90% of the population at some point in their lives. While most frequently observed in adolescents and young adults, an increasing number of patients over the age of 25- long after the period of puberty- are presenting with this problem. The pathogenesis of acne is complex, involving sebaceous gland hyperactivity, follicular hyperkeratosis, excessive proliferation of Cutibacterium acnes, and inflammation, all of which lead to a disruption of skin homeostasis. The causes of this deregulation are primarily attributed to hormonal imbalances, particularly the influence of androgens, as well as carbohydrate metabolism dysfunction and chronic stress. For decades, several groups of medications have been used interchangeably, including isotretinoin, hormonal contraceptives, antibiotics, spironolactone, and various topical agents. Although these treatments have proven effective in many cases, a significant proportion of patients still face side effects, lack of clinical improvement, or disease recurrence. After many years without the introduction of any innovative medication, a new option has emerged for patients struggling with acne vulgaris: clascoterone. Its mechanism of action consists of blocking androgen receptors in the skin, which suppresses sebaceous gland hyperactivity and reduces inflammation. As a topical preparation, it carries a much lower risk of systemic side effects than oral treatments. In this article, we aim to present this new drug in comparison to currently available therapeutic options, looking forward to a potential breakthrough in the treatment of this common dermatosis.
References
Abtahi-Naeini, B., Sattari, H., Rastegarnasab, F., & Seyedyousefi, S. (2025). Efficacy and safety of oral isotretinoin in plane warts: A systematic review on clinical studies. Scientifica, 2025, Article 4242268. https://doi.org/10.1155/sci5/4242268
Agamia, N. F., El Mulla, K. F., Alsayed, N. M., Ghazala, R. M., El Maksoud, R. E. A., Abdelmeniem, I. M., Talaat, I. M., Zaki, I. I., Sabah, R. M., & Melnik, B. C. (2023). Isotretinoin treatment upregulates the expression of p53 in the skin and sebaceous glands of patients with acne vulgaris. Archives of Dermatological Research, 315(5), 1355–1365. https://doi.org/10.1007/s00403-022-02508-y
Alemany, M. (2022). The roles of androgens in humans: Biology, metabolic regulation and health. International Journal of Molecular Sciences, 23(19), Article 11952. https://doi.org/10.3390/ijms231911952
Arowojolu, A. O., Gallo, M. F., Lopez, L. M., & Grimes, D. A. (2012). Combined oral contraceptive pills for treatment of acne. The Cochrane Database of Systematic Reviews, 2012(7), Article CD004425. https://doi.org/10.1002/14651858.CD004425.pub6
Baldwin, H., & Tan, J. (2021). Effects of diet on acne and its response to treatment. American Journal of Clinical Dermatology, 22(1), 55–65. https://doi.org/10.1007/s40257-020-00542-y
Barrea, L., Verde, L., Annunziata, G., Antiga, E., Camajani, E., Caprio, M., Carbonelli, M. G., Carducci, A., Cava, E., Di Marco, G., Grassi, D., Guida, S., Martinelli, B., Marzano, A. V., Moltrasio, C., Petrelli, M., Prignano, F., Rongioletti, F., Savastano, S., et al. (2025). Medical nutrition therapy in dermatological diseases: A joint consensus statement of the Italian Association of Dietetics and Clinical Nutrition (ADI), the Italian Society of Dermatology and Sexually Transmitted Diseases (SIDeMaST), the Italian Society of Nutraceuticals (SINut), Club Ketodiets and Nutraceuticals “KetoNut-SINut” and the Italian Society of Endocrinology (SIE), Club Nutrition, Hormones and Metabolism. Current Obesity Reports, 14(1), Article 42. https://doi.org/10.1007/s13679-025-00630-2
Buendía-González, F. O., Legorreta-Herrera, M., Buendía-González, F. O., & Legorreta-Herrera, M. (2022). The similarities and differences between the effects of testosterone and DHEA on the innate and adaptive immune response. Biomolecules, 12(12), Article 1768. https://doi.org/10.3390/biom12121768
Bungau, A. F., Radu, A. F., Bungau, S. G., Vesa, C. M., Tit, D. M., & Endres, L. M. (2023). Oxidative stress and metabolic syndrome in acne vulgaris: Pathogenetic connections and potential role of dietary supplements and phytochemicals. Biomedicine & Pharmacotherapy, 164, Article 115003. https://doi.org/10.1016/j.biopha.2023.115003
Celasco, G., Moro, L., Bozzella, R., Ferraboschi, P., Bartorelli, L., Quattrocchi, C., & Nicoletti, F. (2004a). Biological profile of cortexolone 17alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist. Arzneimittel-Forschung, 54(12), 881–886. https://doi.org/10.1055/s-0031-1297043
Celasco, G., Moro, L., Bozzella, R., Ferraboschi, P., Bartorelli, L., Quattrocchi, C., & Nicoletti, F. (2004b). Biological profile of cortexolone 17alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist. Arzneimittel-Forschung, 54(12), 881–886. https://doi.org/10.1055/s-0031-1297043
Charny, J. W., Choi, J. K., & James, W. D. (2017). Spironolactone for the treatment of acne in women, a retrospective study of 110 patients. International Journal of Women’s Dermatology, 3(2), 111–115. https://doi.org/10.1016/j.ijwd.2016.12.002
Chen, W., Thiboutot, D., & Zouboulis, C. C. (2002). Cutaneous androgen metabolism: Basic research and clinical perspectives. Journal of Investigative Dermatology, 119(5), 992–1007. https://doi.org/10.1046/j.1523-1747.2002.00613.x
Clascoterone. (2006). In Drugs and Lactation Database (LactMed®). National Institute of Child Health and Human Development. http://www.ncbi.nlm.nih.gov/books/NBK588734/
Clascoterone (Winlevi). (n.d.).
Clinical review. (2025). In Clascoterone (Winlevi): Therapeutic area: Acne vulgaris: Reimbursement review. Canadian Agency for Drugs and Technologies in Health. https://www.ncbi.nlm.nih.gov/books/NBK616783/
Comprehensive dermatologic drug therapy. (n.d.). ScienceDirect. Retrieved March 2, 2026, from http://www.sciencedirect.com:5070/book/monograph/9780323612111/comprehensive-dermatologic-drug-therapy
Cornejo, M. P., Hentges, S. T., Maliqueo, M., Coirini, H., Becu-Villalobos, D., & Elias, C. F. (2016). Neuroendocrine regulation of metabolism. Journal of Neuroendocrinology, 28(7), Article e12395. https://doi.org/10.1111/jne.12395
Del Rosso, J. Q., Kircik, L. H., Stein Gold, L., & Thiboutot, D. (2020). Androgens, androgen receptors, and the skin: From the laboratory to the clinic with emphasis on clinical and therapeutic implications. Journal of Drugs in Dermatology, 19(3), 30–35.
Dhillon, S. (2020). Clascoterone: First approval. Drugs, 80(16), 1745–1750. https://doi.org/10.1007/s40265-020-01417-6
Dreno, B., Thiboutot, D., Gollnick, H., Bettoli, V., Kang, S., Leyden, J. J., Shalita, A., Torres, V., & Global Alliance to Improve Outcomes in Acne. (2014). Antibiotic stewardship in dermatology: Limiting antibiotic use in acne. European Journal of Dermatology, 24(3), 330–334. https://doi.org/10.1684/ejd.2014.2309
Elsaie, M. L. (2016). Hormonal treatment of acne vulgaris: An update. Clinical, Cosmetic and Investigational Dermatology, 9, 241–248. https://doi.org/10.2147/CCID.S114830
Ganceviciene, R., & Zouboulis, C. C. (2010). Isotretinoin: State of the art treatment for acne vulgaris. Journal der Deutschen Dermatologischen Gesellschaft, 8(Suppl. 1), S47–S59. https://doi.org/10.1111/j.1610-0387.2009.07238.x
Harris, C. (2021). Clascoterone (Winlevi) for the treatment of acne. American Family Physician, 104(1), 93–94.
Hebert, A., Thiboutot, D., Stein Gold, L., Cartwright, M., Gerloni, M., Fragasso, E., & Mazzetti, A. (2020). Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: Two phase 3 randomized clinical trials. JAMA Dermatology, 156(6), 621–630. https://doi.org/10.1001/jamadermatol.2020.0465
Issa, N. T., Baldwin, H., Wroblewski, K., & Kircik, L. (2025). The dark side of oral antibiotics: Adverse events of consideration in dermatology. Journal of Drugs in Dermatology, 24(11), s4–s12. https://doi.org/10.36849/JDD.99182
Karakus, E., Schmid, A., Schäffler, A., Wudy, S. A., & Geyer, J. (2025). Intracrine formation of steroid hormones in breast cancer, epidermal keratinocyte, dermal fibroblast, and adipocyte cell lines measured by LC-MS/MS. International Journal of Molecular Sciences, 26(3), Article 1188. https://doi.org/10.3390/ijms26031188
Kim, H. J., Kim, Y. H., Kim, H. J., & Kim, Y. H. (2024). Exploring acne treatments: From pathophysiological mechanisms to emerging therapies. International Journal of Molecular Sciences, 25(10), Article 5302. https://doi.org/10.3390/ijms25105302
Kurokawa, I., Danby, F. W., Ju, Q., Wang, X., Xiang, L. F., Xia, L., Chen, W., Nagy, I., Picardo, M., Suh, D. H., Ganceviciene, R., Schagen, S., Tsatsou, F., & Zouboulis, C. C. (2009). New developments in our understanding of acne pathogenesis and treatment. Experimental Dermatology, 18(10), 821–832. https://doi.org/10.1111/j.1600-0625.2009.00890.x
Kutlu, Ö., Karadağ, A. S., & Wollina, U. (2023). Adult acne versus adolescent acne: A narrative review with a focus on epidemiology to treatment. Anais Brasileiros de Dermatologia, 98(1), 75–83. https://doi.org/10.1016/j.abd.2022.01.006
Layton, A. (2009). The use of isotretinoin in acne. Dermato-Endocrinology, 1(3), 162–169. https://doi.org/10.4161/derm.1.3.9364
Layton, A. M., & Ravenscroft, J. (2023). Adolescent acne vulgaris: Current and emerging treatments. The Lancet Child & Adolescent Health, 7(2), 136–144. https://doi.org/10.1016/S2352-4642(22)00314-5
Li, D., Zhou, Z., Yang, X., Zhang, Q., Xu, J., Zouboulis, C. C., Xiang, Q., Zhang, S., Li, D., Zhou, Z., Yang, X., Zhang, Q., Xu, J., Zouboulis, C. C., Xiang, Q., & Zhang, S. (2025). A comprehensive review: The bidirectional role of sebum in skin health. Bioengineering, 12(12), Article 1333. https://doi.org/10.3390/bioengineering12121333
Li, Y., Hu, X., Dong, G., Wang, X., & Liu, T. (2024). Acne treatment: Research progress and new perspectives. Frontiers in Medicine, 11, Article 1425675. https://doi.org/10.3389/fmed.2024.1425675
Manjaly, C., Martinez, J., Barbieri, J., & Mostaghimi, A. (2023). Clascoterone for treatment of acne. Drugs of Today, 59(2), 71–81. https://doi.org/10.1358/dot.2023.59.2.3507749
Mazzetti, A., Moro, L., Gerloni, M., & Cartwright, M. (2019). Pharmacokinetic profile, safety, and tolerability of clascoterone (cortexolone 17-alpha propionate, CB-03-01) topical cream, 1% in subjects with acne vulgaris: An open-label phase 2a study. Journal of Drugs in Dermatology, 18(6), 563.
Mørch, L. S., Skovlund, C. W., Hannaford, P. C., Iversen, L., Fielding, S., & Lidegaard, Ø. (2017). Contemporary hormonal contraception and the risk of breast cancer. The New England Journal of Medicine, 377(23), 2228–2239. https://doi.org/10.1056/NEJMoa1700732
Morford, J., Wu, S., & Mauvais-Jarvis, F. (2018). The impact of androgen actions in neurons on metabolic health and disease. Molecular and Cellular Endocrinology, 465, 92–102. https://doi.org/10.1016/j.mce.2017.09.001
Nast, A., Dréno, B., Bettoli, V., Bukvic Mokos, Z., Degitz, K., Dressler, C., Finlay, A. Y., Haedersdal, M., Lambert, J., Layton, A., Lomholt, H. B., López-Estebaranz, J. L., Ochsendorf, F., Oprica, C., Rosumeck, S., Simonart, T., Werner, R. N., & Gollnick, H. (2016). European evidence-based (S3) guideline for the treatment of acne—Update 2016—Short version. Journal of the European Academy of Dermatology and Venereology, 30(8), 1261–1268. https://doi.org/10.1111/jdv.13776
Nast, A., Dréno, B., Bettoli, V., Degitz, K., Erdmann, R., Finlay, A. Y., Ganceviciene, R., Haedersdal, M., Layton, A., López-Estebaranz, J. L., Ochsendorf, F., Oprica, C., Rosumeck, S., Rzany, B., Sammain, A., Simonart, T., Veien, N. K., Živković, M. V., Zouboulis, C. C., & Gollnick, H. (2012). European evidence-based (S3) guidelines for the treatment of acne. Journal of the European Academy of Dermatology and Venereology, 26(Suppl. 1), 1–29. https://doi.org/10.1111/j.1468-3083.2011.04374.x
Peterson, H., Kircik, L., & Armstrong, A. W. (2023). Clascoterone cream 1%: Mechanism of action, efficacy, and safety of a novel, first-in-class topical antiandrogen therapy for acne. Journal of Drugs in Dermatology, 22(6), SF350992s7–SF350992s14.
Reynolds, R. V., Yeung, H., Cheng, C. E., Cook-Bolden, F., Desai, S. R., Druby, K. M., Freeman, E. E., Keri, J. E., Gold, L. F. S., Tan, J. K. L., Tollefson, M. M., Weiss, J. S., Wu, P. A., Zaenglein, A. L., Han, J. M., & Barbieri, J. S. (2024). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology, 90(5), 1006.e1–1006.e30. https://doi.org/10.1016/j.jaad.2023.12.017
Rosette, C., Agan, F. J., Mazzetti, A., Moro, L., & Gerloni, M. (2019). Cortexolone 17α-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro. Journal of Drugs in Dermatology, 18(5), 412–418.
Rosette, C., Rosette, N., Mazzetti, A., Moro, L., & Gerloni, M. (2019). Cortexolone 17α-propionate (clascoterone) is an androgen receptor antagonist in dermal papilla cells in vitro. Journal of Drugs in Dermatology, 18(2), 197–201.
Samuels, D. V., Rosenthal, R., Lin, R., Chaudhari, S., & Natsuaki, M. N. (2020). Acne vulgaris and risk of depression and anxiety: A meta-analytic review. Journal of the American Academy of Dermatology, 83(2), 532–541. https://doi.org/10.1016/j.jaad.2020.02.040
Santhosh, P., & George, M. (2021). Clascoterone: A new topical anti-androgen for acne management. International Journal of Dermatology, 60(12), 1561–1565. https://doi.org/10.1111/ijd.15752
Schiffer, L., Kempegowda, P., Arlt, W., & O’Reilly, M. W. (2017). Mechanisms in endocrinology: The sexually dimorphic role of androgens in human metabolic disease. European Journal of Endocrinology, 177(3), R125–R143. https://doi.org/10.1530/EJE-17-0124
Skovlund, C. W., Mørch, L. S., Kessing, L. V., & Lidegaard, Ø. (2016). Association of hormonal contraception with depression. JAMA Psychiatry, 73(11), 1154–1162. https://doi.org/10.1001/jamapsychiatry.2016.2387
Sutaria, A. H., Masood, S., Saleh, H. M., & Schlessinger, J. (2023). Acne vulgaris. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/sites/books/NBK459173/
Taieb, A., Feryel, A., Taieb, A., & Feryel, A. (2024). Deciphering the role of androgen in the dermatologic manifestations of polycystic ovary syndrome patients: A state-of-the-art review. Diagnostics, 14(22), Article 2578. https://doi.org/10.3390/diagnostics14222578
Thiboutot, D., Gollnick, H., Bettoli, V., Dréno, B., Kang, S., Leyden, J. J., Shalita, A. R., Lozada, V. T., Berson, D., Finlay, A., Goh, C. L., Herane, M. I., Kaminsky, A., Kubba, R., Layton, A., Miyachi, Y., Perez, M., Martin, J. P., Ramos-E-Silva, M., et al. (2009). New insights into the management of acne: An update from the Global Alliance to Improve Outcomes in Acne group. Journal of the American Academy of Dermatology, 60(5 Suppl.), S1–S50. https://doi.org/10.1016/j.jaad.2009.01.019
Trifu, V., Tiplica, G.-S., Naumescu, E., Zalupca, L., Moro, L., & Celasco, G. (2011). Cortexolone 17α-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris: A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0.05% cream. The British Journal of Dermatology, 165(1), 177–183. https://doi.org/10.1111/j.1365-2133.2011.10332.x
Vinogradova, Y., Coupland, C., & Hippisley-Cox, J. (2015). Use of combined oral contraceptives and risk of venous thromboembolism: Nested case-control studies using the QResearch and CPRD databases. BMJ, 350, Article h2135. https://doi.org/10.1136/bmj.h2135
Weill, A., Nguyen, P., Labidi, M., Cadier, B., Passeri, T., Duranteau, L., Bernat, A.-L., Yoldjian, I., Fontanel, S., Froelich, S., & Coste, J. (2021). Use of high dose cyproterone acetate and risk of intracranial meningioma in women: Cohort study. BMJ, 372, Article n37. https://doi.org/10.1136/bmj.n37
Winiarska-Mieczan, A., Samolińska, W., & Kowalczuk-Vasilev, E. (2022). Czynniki żywieniowe a stan skóry, włosów i paznokci (1st ed.). Wydawnictwo Uniwersytetu Przyrodniczego w Lublinie. https://doi.org/10.24326/mon.2022.1
Zaenglein, A. L., Pathy, A. L., Schlosser, B. J., Alikhan, A., Baldwin, H. E., Berson, D. S., Bowe, W. P., Graber, E. M., Harper, J. C., Kang, S., Keri, J. E., Leyden, J. J., Reynolds, R. V., Silverberg, N. B., Gold, L. F. S., Tollefson, M. M., Weiss, J. S., Dolan, N. C., Sagan, A. A., et al. (2016). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology, 74(5), 945–973.e33. https://doi.org/10.1016/j.jaad.2015.12.037
Zouboulis, C. C., & Degitz, K. (2004). Androgen action on human skin: From basic research to clinical significance. Experimental Dermatology, 13(Suppl. 4), 5–10. https://doi.org/10.1111/j.1600-0625.2004.00255.x
Zouboulis, C. C., & Rabe, T. (2010). Hormonal antiandrogens in acne treatment. Journal der Deutschen Dermatologischen Gesellschaft, 8(Suppl. 1), S60–S74. https://doi.org/10.1111/j.1610-0387.2009.07171.x
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Joanna Piasecka, Bartosz Gołembiewski, Grzegorz Mulski, Martyna Manicka, Michał Baranowicz, Weronika Mazurkiewicz, Zuzanna Borecka, Agnieszka Marta Sobczak, Alicja Szymczak, Anna Jaworowicz
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
